VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The move matters because it could significantly reduce animal testing while accelerating clinical advancement and lowering development costs and timelines—a critical consideration for investors and patients awaiting new cancer treatments.
The company has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. In a key demonstration, VERAXA evaluated its lead BiTAC-TCE and bsADC candidates using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. This panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. The combined BiTAC consistently induced potent T cell-mediated killing across the panel, supporting the company’s dual-targeting approach and showing that its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
For investors, the implications are substantial: fewer animals and faster cycles could translate into lower R&D costs and quicker progression to human trials, enhancing the company’s competitive position in the crowded oncology space. The FDA has been encouraging NAMs as part of a broader push to modernize drug development, and VERAXA’s alignment with these methods may smooth regulatory interactions. To view the full press release, visit https://ibn.fm/9YRJw.
VERAXA was founded on scientific breakthroughs at the European Molecular Biology Laboratory and is advancing a pipeline of ADCs and proprietary BiTAC formats. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA. BioMedWire, a specialized communications platform focused on biotechnology and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also offers article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
